| Home |
 |
| |
 |
| |
 |
| |
 |
| |
 |
| |
 |
| |
 |
Last updated on
February 1st, 2009
February 1st, 2009
Junho Chung's Laboratory
Our laboratory is concerned with problems in molecular
biology, immunology and medicine. Many of our studies
involve studying nature's strategies in creating
antibodies and improving them, or inventing new
approach to prepare antibodies with specific functions,
such as destroying cancer cells or blocking metastasis.
A major focus of our laboratory is expanding antibody
binding site on protein into non-natural epitope regions.
To achieve this, we grafted a protein interaction motif
into a paratope region of human antibody and
successfully generated antibody specific to non-epitope
region of an integrin. And by immunization of a protein
complex, we produced antibodies against an epitope
induced on one protein of the complex through protein-
protein interaction.
Our work stretches to optimization and utilization of
antibodies for therapeutic purposes. To accomplish this,
our group has developed a unique streamline work-flow
covering humanization, de-immunization and process
optimization. Two of our antibodies, anti-HGF
(hepatocyte growth factor) antibody and anti-VCAM1
antibody showed efficacy in animal experiments and are
expected to enter preclinical trial in near future
biology, immunology and medicine. Many of our studies
involve studying nature's strategies in creating
antibodies and improving them, or inventing new
approach to prepare antibodies with specific functions,
such as destroying cancer cells or blocking metastasis.
A major focus of our laboratory is expanding antibody
binding site on protein into non-natural epitope regions.
To achieve this, we grafted a protein interaction motif
into a paratope region of human antibody and
successfully generated antibody specific to non-epitope
region of an integrin. And by immunization of a protein
complex, we produced antibodies against an epitope
induced on one protein of the complex through protein-
protein interaction.
Our work stretches to optimization and utilization of
antibodies for therapeutic purposes. To accomplish this,
our group has developed a unique streamline work-flow
covering humanization, de-immunization and process
optimization. Two of our antibodies, anti-HGF
(hepatocyte growth factor) antibody and anti-VCAM1
antibody showed efficacy in animal experiments and are
expected to enter preclinical trial in near future